News | October 02, 2007

Avid Holds Trial for Imaging Compound

October 3, 2007 - Avid Radiopharmaceuticals Inc., a product-focused molecular imaging company, announced today that enrollment has begun in a proof-of-concept phase I clinical trial investigating Avid’s development compound 18F-AV-133 for imaging patients with movement disorders, including Parkinson’s Disease (PD) and essential tremor and dementias, including Dementia with Lewy Bodies (DLB) and Alzheimer’s Disease (AD).

The compound, used with positron emission tomography (PET) imaging, targets vesicular monoamine transporters (VMAT2) in the brain and may enable more accurate and earlier diagnosis of neurodegenerative diseases. This new imaging compound may thus lead to improved disease management for patients and their caregivers. The study will be initially conducted at the University of Michigan and will involve 30 patients.

Avid’s 18F-AV-133 compound may also be useful for improved management of Alzheimer’s Disease (AD) because up to 25 percent of AD patients also have a component of PD or DLB. The goal of this initial trial is to determine whether 18F-AV-133 PET imaging can detect losses in nigrostriatal neurons in the brains of patients with AD, PD and DLB. Patients with overlapping symptoms and disease pathology are often misdiagnosed today.

The VMAT2 study represents the second clinical stage program in Avid’s development pipeline. The company, founded in 2004, is currently conducting a phase one clinical trial of its PET amyloid imaging compound for early detection of AD.

For more information: www.avidrp.com

Related Content

ISMRM Issues Guidelines for MRI Gadolinium Contrast Agents
News | Contrast Media | August 15, 2017
The International Society for Magnetic Resonance in Medicine (ISMRM) has provided new guidance in the use of contrast...
Contrast Media from Bayer, trends in contrast media and developments in contrast media
Feature | Contrast Media | July 28, 2017 | By Dave Fornell
Here are several updates in medical imaging ...
Guerbet Announces Plans to Streamline Contrast Media Portfolio, gadolinium MRI contrast
News | Contrast Media | July 18, 2017
July 18, 2017 — Guerbet recently announced that it will phase out sales throughout the world of two products: Hexabri
ACR Offers Revised Contrast Media in Imaging Manual
News | Contrast Media | July 17, 2017
The American College of Radiology (ACR) recently revised its authoritative guide for the safe and effective use of...
FDA says gadolinium retention in the brain is not a safety issue
Feature | Magnetic Resonance Imaging (MRI) | May 25, 2017
A U.S. Food and Drug Administration (FDA) review of the safety ramifications of gadolinium-based contrast agents for...
Targeted MRI Could Pinpoint Aggressive Prostate Cancers Before They Spread

The ZD2-Gd probe, represented by the orange ball and green arrow, binds to the EDB-FN in the prostate cancer cells with high metastatic potential. This results in a strong MRI signal (upper right). Prostate cancer cells with low metastatic potential have no EDB-FN and so there is no MRI signal (lower right). Credit: Han, et al., Bioconjug Chem-Apr-2017

News | Prostate Cancer | May 24, 2017
A research team funded by the National Institute of Biomedical Imaging and Bioengineering (NIBIB) has engineered a...
Scientists Develop Novel Chemical Dye to Improve MRI Liver Cancer Imaging
News | Magnetic Resonance Imaging (MRI) | May 03, 2017
May 3, 2017 — Scientists from the National University of Singapore (NUS) have developed a novel nanodiamond-based ...
Sponsored Content | Case Study | Contrast Media Injectors | April 13, 2017
The volume of computed tomography (CT) imaging exams continues to grow in the United States,[2] adding pressure to...
PRAC, European Medicines Agency, gadolinium-based contrast agents, safety recommendations, brain MRI
News | Contrast Media | March 13, 2017
The Pharmacovigilance Risk Assessment Committee (PRAC) of the European Medicines Agency recently released new...
Overlay Init